Maria Isabel Manley > Sidley Austin LLP > London, England > Lawyer Profile
Sidley Austin LLP Offices

70 St Mary Axe
London
EC3A 8BE
England
- Firm Profile
- Go to...
Maria Isabel Manley

Work Department
Food, Drug and Medical Device
Position
Partner
Career
MARIA ISABEL MANLEY leads Sidley’s Life Sciences team in London and is a distinguished thought leader and adviser on EU and UK regulatory law. She represents development-stage, specialty and established global life sciences companies in a broad spectrum of matters, both contentious and non-contentious, including bet-the-company regulatory matters, investigations and court challenges. Marie is experienced in advising on issues arising during the life cycle of medicinal products, including optimisation of IP regulatory rights, advertising, product liability, interaction between competition and regulatory law; as well as market access issues (namely representing and advising clients in their interaction with HTA bodies such as NICE and payors such as NHS England). Marie has an unprecedented track record of successfully advising clients on the best strategy to overcome the challenges of Health Technology Assessments, to present the best value proposition to payors, including reliance on RWE to address gaps in clinical trial data. Marie has successfully represented clients in their interaction with NICE as well as challenging unfavourable NICE decisions before the NICE appeal panel and the English courts. Marie has represented a number of the world’s leading pharmaceutical and life sciences companies in litigation before the European and English Courts, as well as before the regulatory authorities, including the European Commission, the European and UK medicines authorities (EMA and MHRA), including successfully representing pharma companies in the enforcement of their orphan-drug exclusivity.
Lawyer Rankings
London > Industry focus > Life sciences and healthcare
(Leading partners)Known for its ability to handle regulatory issues relating to orphan drugs, cell and gene therapy products, and digital health tools, Sidley Austin LLP is additionally active across areas including product liability, cybersecurity, M&A, and collaborations and licencing. Maria Isabel Manley leads the life sciences team for Sidley’s office in London and frequently brings her knowledge of EU and UK regulatory and competition law to bear when representing clients before regulatory authorities. Robert Darwin is a key contact for global life sciences and healthcare corporations looking to do transactions. James Wood is well-placed to handle M&A work in the sector. Solicitor advocate Chris Boyle, and Zina Chatzidimitriadou, who excels in market access strategy matters, are further recommended.
Lawyer Rankings
- Leading partners London > Industry focus > Life sciences and healthcare
- Life sciences and healthcare London > Industry focus
Top Tier Firm Rankings
Firm Rankings
- Finance > Debt capital markets
- Finance > Derivatives and structured products
- Industry focus > Life sciences and healthcare
- Finance > Securitisation
- Finance > Acquisition finance
- Finance > Corporate restructuring & insolvency
- TMT (technology, media and telecoms) > Fintech: regulatory
- Projects, energy and natural resources > Infrastructure: M&A and acquisition financing
- Insurance > Insurance: corporate and regulatory
- Corporate and commercial > Private equity: transactions – high-value deals (£500m+)
- Dispute resolution > Banking litigation: investment and retail
- Real estate > Commercial property: investment
- Corporate and commercial > Corporate tax
- Risk advisory > Data protection, privacy and cybersecurity
- Corporate and commercial > Financial services: contentious
- Corporate and commercial > Financial services: non-contentious/regulatory
- Crime, fraud and licensing > Fraud: white-collar crime (advice to individuals)
- Risk advisory > Regulatory investigations and corporate crime (advice to corporates)
- Dispute resolution > Commercial litigation: premium
- Investment fund formation and management > Private funds
- Corporate and commercial > EU and competition
- Corporate and commercial > M&A: Upper Mid-Market And Premium Deals, £750m+
- Real estate > Property finance